top of page

NCI-2020-02319

A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib inPatients with Metastatic Triple Negative Breast Cancer

This clinical trial is evaluating the safety and whether this combination therapy using Eribulin and Copanlisib stops cancer growth in patients with metastatic triple-negative breast cancer. Eribulin is a type of chemotherapy drug that is commonly used to treat metastatic breast cancer, while Copanlisib is a targeted therapy that inhibits the PI3K pathway, which is often activated in triple-negative breast cancer. The trial is investigating whether the combination of these two drugs can improve treatment outcomes in this patient population.

Metastatic: cancer that has spread from its original location or organ to other parts of the body.

Triple-Negative: It is a type of breast cancer in which cells do not have estrogen receptors (ER), progesterone receptors (PR), and HER-2 receptors.

For more information about the trial, click the link below:

Clinical Trial Site: Columbia


To see all available clinical trials click here.



Recent Posts

See All

NCI-2023-06503

An open-label, single-arm, Phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of LS301-IT in female patients undergoing partial mastectomy and sentinel lymph node biopsy (SLNB)

NCI-2022-02453

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer Doctors are conducting a study to test the safety and effectiveness of a new medicine called

NCI-2022-07265

EAY191-N2 Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1 A ComboMATC

コメント


bottom of page